Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a type of chronic inflammatory arthritis primarily affecting the spine and pelvis, leading to pain, stiffness, and potential fusion of the vertebrae, often accompanied by eye and bowel problems. It involves genetic and environmental factors, with a strong association to the HLA-B27 antigen, and is diagnosed through symptoms, medical imaging, and blood tests.
Health Outcomes
- Altered Serum Immune Protein Levels
- Changed Pressure Pain Threshold
- Decreased TNFα Levels
- Elevated Interleukin-17 Levels
- Elevated Serum Metabolites in Response to Inflammation
- Enhanced Immunoregulatory Molecule Activity
- Enhanced Innate Immune Response
- Improved Antioxidant and Anti-Inflammatory Response
- Improved Bone Health
- Improved Bone Preservation
- Improved Chronic Inflammation
- Improved Clinical Disease Activity
- Improved Clinical Remission
- Improved Connective Tissue Attachment Levels
- Improved Disease Activity Index Score
- Improved Flexed Arm Range of Motion
- Improved Flexibility
- Improved Hip Joint Motion
- Improved Joint Function
- Improved Joint Pain
- Improved Musculoskeletal Disease Symptom
- Improved Orthopedic Function
- Improved Oswestry Disability Index Score
- Improved Pain Score
- Improved Patient Global Assessment
- Improved Physician Global Assessment
- Improved Range of Motion
- Improved Stiffness
- Improved Symptom Control in Degenerative Joint Disease
- Improved Th17/Treg Ratio
- Increased Anti-Inflammatory Levels
- Increased Anti-Osteoclastogenic Cytokine Production
- Increased Bone Density
- Increased Bone Formation Rate
- Increased Bone Formation/Resorption Ratio
- Increased Bone Volume
- Increased IL-12 Levels
- Increased IL-17 Levels
- Increased IL-17A Level
- Increased IL-22-Producing CD4+ T Cell Count
- Increased Inflammatory Mediator Production
- Increased Inflammatory Response
- Increased Lumbar Spine Bone Mineral Density
- Increased Rheumatoid Arthritis Risk
- Increased Spinal Fusion Rate
- Increased T Cell Activation
- Increased T Cell Activation Marker Level
- Increased TNF-alpha Levels in Macrophages
- Increased Th1-Associated Cytokine Release
- Increased Th17 Polarization
- Increased Tumor Necrosis Factor-Alpha Production by Dendritic Cells
- Inflammatory Disease Protection
- Matured Antigen-Presenting Cells
- Modulated Humoral Inflammation
- No Change in C-Reactive Protein
- No Significant Change in Tumor Necrosis Factor Alpha Levels
- Prevention and Treatment of Inflammatory Diseases
- Reduced Aggravation of Chronic Inflammation
- Reduced Arthralgia
- Reduced Arthritis Incidence
- Reduced Arthritis Score
- Reduced Arthritis Symptoms
- Reduced Bone Erosion
- Reduced Bone Resorption Marker
- Reduced C-Reactive Protein Levels
- Reduced Clinical Symptoms of Arthritis
- Reduced Disease Activity
- Reduced Disease Activity Index
- Reduced Disease Activity Index (DAI) Levels
- Reduced Disease Activity Index Scores
- Reduced Disease Activity Marker Level
- Reduced Disease Activity Score
- Reduced High-Sensitive C-Reactive Protein Level
- Reduced IL-17 Production in Splenocytes
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Disease Activity
- Reduced Inflammatory Factor Level
- Reduced Inflammatory Response to Inflammatory Stimulus
- Reduced Inflammatory Stress
- Reduced Interleukin-17 Level
- Reduced Joint Damage
- Reduced Joint Inflammation
- Reduced Joint Stiffness
- Reduced Joint Swelling
- Reduced Joint Tenderness
- Reduced Levels of Interleukin-17
- Reduced Levels of Receptor Activator of Nuclear Factor-kappa B Ligand
- Reduced Muscle Joint Pain
- Reduced Musculoskeletal Dysfunction
- Reduced Musculoskeletal Pain
- Reduced Pain During Movement
- Reduced Pain Levels
- Reduced Pain Scale
- Reduced Pain at Rest
- Reduced Plasma Tumor Necrosis Factor-α Levels
- Reduced Pro-Inflammatory Immune Activity
- Reduced Pro-inflammatory Gene Transcription
- Reduced Proinflammatory Factor Levels
- Reduced Risk of Chronic Inflammatory Diseases
- Reduced Serum TNF-α Levels
- Reduced Serum Tumor Necrosis Factor-α
- Reduced Severity of Symptoms Per Day
- Reduced Shoulder Stiffness
- Reduced Stiffness
- Reduced Synovial Infiltration
- Reduced TH17 Response
- Reduced TNF Production
- Reduced TNF-alpha Level
- Reduced TNF-α Concentration
- Reduced TNF-α Levels
- Reduced TNF-α Secretion
- Reduced TNF-α Signaling
- Reduced Tender Joint Count
- Reduced Time to Relief of Lower Back Pain
- Reduced Tumor Necrosis Factor Alpha
- Reduced Tumor Necrosis Factor Alpha Production
- Reduced Tumor Necrosis Factor-α (TNF-α)
- Reduced Tumor Necrosis Factor-α Levels
- Relieved Joint Pain
- Safe Drug Administration
- Stable Inflammatory Responses
- Suppressed TNF-α Induced Genes
- Unchanged Body Weight